NCT05293665: An overdue trial by Vaxxinity, Inc.
This trial is overdue. It was due to report 1 year, 9 months ago.
Think we've made a mistake? Before contacting us, review the criteria in our paper. In particular, bear in mind the following:
- We can only rely on the structured data that sponsors put into the registry: they may enter incorrect or incomplete data.
- Reporting in a journal is not enough. The FDAAA rules state that the trial must be reported on ClinicalTrials.gov.
- Terminated trials are required to report results. Only withdrawn trials (which never recruited a single patient) are not.
Full data
| Full entry on ClinicalTrials.gov | NCT05293665 |
|---|---|
| Title | A Phase 3 Multi-Center International, Randomized, Active-Controlled Platform Trial to Compare Homologous Boost of Authorized COVID-19 Vaccines and Heterologous Boost With UB-612 Vaccine |
| Results Status | Overdue |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | March 16, 2022 |
| Completion date | Nov. 30, 2022 |
| Required reporting date | Nov. 30, 2023, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Aug. 26, 2025 |
| Days late | 635 |